pfizer glp 1 drug pulls out of GLP-1 race after safety concerns The enormous popularity of new
Description
One study reported that 43.8% of participants who discontinued treatment did so due to nausea and vomiting, while 36.8% stopped because of gastrointestinal discomfort [14]
Diabetes Care (2022) 45(Suppl 1):S12543
These documented strategies create measurable cost reductions while maintaining treatment safety and effectiveness
Buteau, J., Foisy, S., Joly, E
Endocr Oncol
While studying GLP-1s and how effectively they treat diabetes, researchers discovered how significantly these medications can also affect a persons appetite, satiety, and food intake
